• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Identifying clinical correlates of drinking clusters during treatment for alcohol use disorder

Abstract

Background and Objectives

Despite the availability of treatments for alcohol use disorder (AUD), relapse prevalence and health-related consequences associated with AUD remains high. Using data-driven approaches that enhance generalizability can help elucidate relationships between treatment outcomes and alcohol consumption, aiding in the discovery of novel treatment targets for AUD subtypes.

Methods

We merged data (n = 2045) across four Phase 2 randomized clinical trials affiliated with the NIAAA Clinical Investigations Group and a Phase 3 trial (NIAAA Sponsored). Participants were clustered based on self-reported drinking during treatment maintenance. A gradient boosted machine learning model with end-of-treatment clinical features was used to predict the clusters we identified.

Results

We identified a three-cluster solution corresponding to low (M
Standard Drinking Units (SDU) = 1.68, n = 1677), moderate (M
SDU = 6.70, n = 253), and high (M
SDU = 12.92, n = 115) clusters of alcohol consumption during treatment maintenance. We achieved modest prediction of the clusters (AccuracyTrain = 71.0%; AUCTrain = 0.79) using demographics and end-of-treatment clinical and biological assessments. Between-cluster differences were observed between low and high clusters on measures of depression and anxiety (M
Difference = 0.49, SE = 0.13, p = .004), drinking consequences (M
Difference = 1.02, SE = 0.13, p < .001) and liver functioning (0.39 ≤ M
Difference ≤ 0.52, 0.12 ≤ SE ≤ 0.13, 0.001 ≤ p ≤ .005)

Discussion and Conclusions

These findings suggest that generalizable clusters of alcohol consumption exist across these clinical trials characterized by core demographics, clinical, and biological phenotypes, irrespective of the treatment received. We further show that some assessments may not be useful in distinguishing between higher levels of consumption.

Scientific Significance

Identifying predictive features of AUD subtypes, across different phases of treatment, can assist clinicians in identifying individuals who require additional support.

Read the full article ›

Posted in: Journal Article Abstracts on 03/03/2026 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2026 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice